Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00165243 · ClinicalTrials.gov registry record · Phase 2
Tangential Radiation Therapy Without Axillary Dissection in Breast Cancer
A Phase 2 study of Early Stage Breast Cancer, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 2
- Study locations
NCT00165243 is a Phase 2 study of Early Stage Breast Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 100 participants, below the 409-participant average among 21 other Early Stage Breast Cancer trials with a reported enrollment target (76% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00165243, a Phase 2 study of Early Stage Breast Cancer, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate whether treatment to the axilla (area under the arm) can be safely minimized by omitting axillary surgery and full axillary radiation therapy and replacing it with radiation therapy to the breast and lower axilla.
Conditions Studied
Interventions
- PROCEDURE Tangential radiation
Study Locations (2)
Massachusetts
- Dana-Farber Cancer Institute - Boston
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 1998-09 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00165243
The ClinicalTrials.gov registry entry for NCT00165243 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 409-participant average among 21 other Early Stage Breast Cancer trials with a reported enrollment target (76% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Early Stage Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Tangential radiation is the first listed.
NCT00165243 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00165243 about?
NCT00165243 is a clinical study titled "Tangential Radiation Therapy Without Axillary Dissection in Breast Cancer". The purpose of this study is to evaluate whether treatment to the axilla (area under the arm) can be safely minimized by omitting axillary surgery and full axillary radiation therapy and replacing it with radiation therapy to the breast and lower axilla.
What is the current status of trial NCT00165243?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 1998-09. Estimated completion is 2016-12.
What conditions does trial NCT00165243 study?
This clinical trial studies the following conditions: Early Stage Breast Cancer.
What interventions are being tested in trial NCT00165243?
The interventions under investigation include: Tangential radiation (PROCEDURE).
Who is sponsoring clinical trial NCT00165243?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00165243 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Early Stage Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients
RECRUITING · Phase 2
-
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RECRUITING · Phase 2
-
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
RECRUITING · Phase 2
-
Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
RECRUITING · Phase 2
-
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
RECRUITING · Phase 2
-
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.